Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Phase 3Recruiting
- Lead sponsor
- Arcus Biosciences, Inc. (Industry)
- Enrollment
- 720 (estimated)
- Start date
- 8 Sep 2025
- Primary completion
- Apr 2028 (estimated)
- Study completion
- 1 Dec 2030
- Last update posted
- 26 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Casdatifan Drug
- Cabozantinib Drug
- Placebo Drug
Conditions and primary outcome
- Metastatic Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
Primary outcome
Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 (up to approximately 33 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedDiscovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.
Journal of medicinal chemistry · 2026 Jun 25
PubMed 42246926 (opens in a new tab)DOI 10.1021/acs.jmedchem.5c03724 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07011719 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.